mab-216
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2004 (NCT00313053)
Timeline
2000s
- Jan 1, 2004
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
CSF1 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109651 ↗
- ChEMBLCHEMBL2109448 ↗
Also known as
- humab 216
- human mab 216
- mab 216
- mab-216
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00313079 | Phase 1 | May 1, 2006 | Stanford University |
| NCT00313053 | Phase 1 | Sep 1, 2004 | National Institutes of Health (NIH), Stanford University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Stanford University | Academic/Hospital | 2 | 2 | 1 | 2004 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2004 |
2 organizations
Page 1 / 1